重组人红细胞生成素治疗肿瘤化疗相关性贫血临床研究  

Clinical observation of erythropoietin in treating the cancer-related anemia after chemotherapy

作　　者：王泽阳[1] 侯梅[1] 王海燕[1] 陈萍[1] 徐聂[1] 赵振华[1] 

机构地区：[1]四川大学华西医院肿瘤中心,四川成都610041

出　　处：《西部医学》2009年第6期912-913,共2页Medical Journal of West China

摘　　要：目的评价重组人红细胞生成素(Recombinant Human Erythropoietin Injection,rHuEPO)治疗肿瘤化疗相关性贫血的疗效和安全性。方法化疗相关性贫血的患者56例,其中治疗组28例行rHuEPO治疗,用法为:150 u/kg.次,皮下注射3次/周,疗程4周;对照组28例未用rHuEPO治疗,余治疗相同。观察rHuEPO对血红蛋白(Hb)、红细胞比容(Hct)及对患者生存质量(QOF)的影响。结果治疗组治疗后Hb水平显著提高,KPS较化疗前无变化,而对照组Hb水平下降,KPS较前下降。结论rHuEPO治疗肿瘤化疗相关性贫血的疗效肯定,安全性高,副反应少,能够改善患者生存质量。Objective To observe the effect of recombinant human erythropoietin （rHuEPO） in cancer-related anemia after chemotherapy. Methods Twenty -eight cases of treated group were treated with rHuEPO 1 for 4 weeks. Twenty -eight cases of control group were treated with support cares. The influence of the rHuEPO on HCT, Hb and quantity of life were observed. Results The Hb and QOF of treated group were higher than that of control group （P〈0. 05）. Conclusion It is effect and safe to treat the cancer-related anemia with rhuEPO.

关 键 词：恶性肿瘤贫血 重组人红细胞生成素 血红蛋白 

分 类 号：R73[医药卫生—肿瘤]